Nancy L. Ascher, Cyrille Féray, Didier Samuel, Michèle Gigou, Valérie Paradis, Marie Françoise David, Catherine Lemonnier – 1 January 1996 – The aim of this open trial was to assess the efficacy and the safety of interferon (IFN) alfa therapy in liver transplant recipients with chronic active hepatitis caused by hepatitis C virus. In July 1991, among 447 liver recipients regularly observed at our institution, 46 had developed HCV‐related chronic active hepatitis defined by piece meal necrosis.

H Shinohara, A Tanaka, T Kitai, N Yanabu, T Inomoto, S Satoh, E Hatano, Y Yamaoka, K Hirao – 1 January 1996 – We continuously measured hepatic absorbance of indocyanine green (ICG) using near‐infrared (NIR) spectroscopy after intravenous bolus injection in rabbits. Hepatic ICG concentration was obtained by subtracting out the absorbance of hemoglobin and other pigments within the liver.

H C Bisgaard, P Nagy, E Santoni‐Rugiu, S S Thorgeirsson – 1 January 1996 – In this study, we used [3H]thymidine labeling of newly synthesized DNA to examine the earliest effects of 2‐acetylaminofluorene (2‐AAF) on the mitotic activation of cells in the adult rat liver, and in situ hybridization analysis to study the expression of three transcription factors (HNF1 beta, HNF3 γ, and HNF4), and two of the genes (α‐fetoprotein [AFP] and albumin) regulated by these factors.

R Romero, J E Lavine – 1 January 1996 – Hepatitis B virus (HBV) DNA contains consensus elements for transactivating proteins whose binding activity in other systems is regulated by inflammatory cytokines. Because HBV replicates within an environment of provoked inflammation, we speculated that the HBV core/pregenomic promoter may be regulated by cytokines produced in response to infection. To evaluate this hypothesis, the HBV core/pregenomic (C/P) promoter and associated cis‐acting elements were placed upstream of a luciferase‐encoding plasmid.

Robert Cywes, P. Robert C. Harvey, Marian A. Packham, Ross Cameron, Steven M. Strasberg – 1 January 1996 – We have previously shown that part of the injury sustained by cold‐preserved livers on reperfusion is the consequence of platelet adhesion to sinusoidal endothelium. The purpose of the present study was to determine whether prostaglandin E1 (PGE1) can reduce the injury and if so, how to maximize this beneficial effect.

J Villeneuve, M Dagenais, P Huet, A Roy, R Lapointe, D Marleau – 1 January 1996 – In cirrhosis, capillarization of sinusoids could result in impaired exchanges between the hepatocytes and the blood perfusing the liver and contribute to liver failure irrespective of the metabolic capacity of the liver. To characterize anomalies of the hepatic microcirculation, we used the multiple‐indicator dilution approach in isolated perfused livers obtained from patients with cirrhosis at the time of transplantation, and from organ donors with normal or near‐normal livers or hepatic steatosis.

Michael F. Sorrell, Byrs W. Shaw – 1 January 1996

1 January 1996

Israel Penn – 1 January 1996 – De novo cancers occurred after transplantation in 8,008 organ allograft recipients, who developed 8,531 different types of malignancy. Three hundred twenty‐four liver recipients developed 329 cancers. There were striking differences in the patterns of neoplasms observed when these were compared with 7,200 tumors that occurred in renal allograft recipients.

W. Kenneth Washburn, Lynt B. Johnson, W. David Lewis, Roger L. Jenkins – 1 January 1996 – Patients with adult polycystic liver disease and massive cystic replacement of the liver may present with severe debilitation and impairment of functional performance or, rarely, with signs of portal hypertension or hepatic dysfunction. In those patients incapacitated by severe hepatomegaly secondary to massive cystic replacement with predominantly small cysts (2 cm) without areas of parenchymal sparing, liver transplantation is a therapeutic option.